The genetic basis of malignant hyperthermia

Israel Medical Association Journal

Volumn 9, Issue 1, 2007, Pages 39-41

  Greenbaum, Iris ^a,b   Weigl, Yuval ^a,b   Pras, Elon ^a,b  

^a GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anesthesia; Dominant inheritance; Genotype phenotype correlation; In vitro muscle cotracture test; Malignant hyperthermia; Mutational hot spot; Ryanodine receptor; Skeletal muscle

Indexed keywords

1,4 DIHYDROPYRIDINE RECEPTOR; ANESTHETIC AGENT; CALCIUM CHANNEL; DANTROLENE; RYANODINE RECEPTOR 1;

AUTOSOMAL DOMINANT INHERITANCE; CALCIUM TRANSPORT; CHROMOSOME 19; CLINICAL FEATURE; DISEASE PREDISPOSITION; GENE INTERACTION; GENE LOCATION; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEALTH CARE COST; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; MUSCLE CONTRACTION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RISK REDUCTION; SARCOPLASMIC RETICULUM;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALIGNANT HYPERTHERMIA;

EID: 33846440550     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Denborough MA. Malignant hyperthermia. Lancet 1998;352:1131-6.
2. Denborough MA, Forster JF, Lovell RR, Maplestone PA, Villiers JD. Anaesthetic deaths in a family. Br J Anaesth 1962;34:395-6.
3. Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA 2005;293:2918-24.
4. Denborough MA, McLean A, Morgan G, Hopkinson KC. Fatal inherited rhabdomylosis and malignant hyperthermia [Letter]. Lancet 1994;343:236-7.
5. Jurkat-Rott K, McCarthy T, Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000;23:4-17.
6. Denborough MA. Sudden infant death syndrome and malignant hyperpyrexia. Med J Aust 1981;1:649-50.
7. Peterson DR, Davis N. Sudden infant death syndrome and malignant hyperthermia diathesis. Aust Paediatr J 1986;22:33-5.
8. King JO, Denborough MA, Zapf PW. Inheritance of malignant hyperthermia. Lancet 1972;1:365-70.
9. King JO, Denborough MA. Anesthetic-induced malignant hyperpyrexia in children. J Pediatr 1973;83:37-40.
10. Shuaib A, Passoke RT, Brownell KW. Central core disease. Clinical features in 13 patients. Medicine 1987;66:389-96.
11. Louis CF, Zualkerman K, Roghair T, Mickelson JR. The effect of volatile anesthetics on calcium regulation by malignant hyperthermia susceptibility sarcoplasmic reticulum. Anesthesiology 1992;77: 114-25.
12. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene - a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004;59:364-73.
13. Moulds FRW, Denborough MH. Identification of susceptibility to malignant hyperthermia. Br Med J 1974;2:245-7.
14. Rosenberg H, Antognini JF, Muldoon S. Testing for malignant hyperthermia. Anesthesiology 2002;96:232-7.
15. Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 1997;41:955-66.
16. Larach MG. Standardization of the caffeine haloten muscle contracture test. North America Malignant Hyperthermia Group. Anesth Analg 1989;69:511-15.
17. Anetseder M, Hager M, Muller CR, Roewer N. Diagnosis of susceptibility to malignant hyperthermia by use of metabolic test. Lancet 2002;359:1579-80.
18. McPherson EW, Taylor CA. The genetics of malignant hyperthermia: evidence for heterogeneity. Am J Med Genet 1982;11:273-85.
19. Ellis FR, Cain PA, Harriman DGF. Multifactorial inheritance of malignant hyperthermia susceptibility. In: Aldrete JA, Britt BA, eds. Proceedings of the 2nd International Symposium on Malignant Hyperthermia 1977. New York: Grime and Stratton, 1978:329-38.
20. Pessah IN, Francini AO, Scales DJ, Waterhouse AL, Casida JE. Calcium-ryanodine receptor complex: solubilization and partial characterization from skeletal muscle junctional sarcoplasmic reticulum vesicles, J Biol Chem 1986;261:8643-8.
21. McCarthy TV, Quane K, Lynch PJ. Ryanodine receptor mutation in malignant hyperthermia and central core disease. Hum Mutat 2000;15:410-17.
22. Monnier N, Kozak-Ribbens G, Krivosic-Horber R, et al, Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Hum Mutat 2005;26:413-25.
23. Galli L, Orrico A, Lorenzini S, et al. Frequency and localization of mutations in the 106 exons of the RYRI gene in 50 individuals with malignant hyperthermia. Hum Mutat 2006;27:830.
24. 2+ release channels. J Clin Invest 2005;115:2033-8.
25. Shy GM, Magee KR. A new congenital non-progressive myopathy. Brain 1956;79:610-21.
26. Wu S, Ibarra MC, Malicdan MC, et al. Central core disease is due to RYRI mutations in More than 90% of patients, Brain 2006;129:1470-80.
27. Engel AG, Gomez MR, Groover RV. Multicore disease. Mayo Clin Proc 1971;10:666-81.
28. Ferreiro A, Estournet B, Chateau D, et al, Multi-minicore disease; searching for boundaries: phenotype analysis of 38 cases. Ann Neurol 2000;48:745-57.
29. Jungbluth H, Zhou H, Hartley L, et al. Minicore myopathy with ophthalmoplegia caused by mutations in the ryanocline receptor type I gene. Neurology 2005;65:1930-5.
30. Robinson RL, Anetseder MJ, Brancadoro V, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 2003;11: 342-8.
31. Robinson RL, Curran JL, Ellis FR, et al. Multiple interacting gene products may influence susceptibility to malignant hyperthermia. Ann Hum Genet 2000;64:307-20.
32. Olckers A, Meyers DA, Meyers S, et al. Adult muscle sodium channel alpha-subunit is a gene candidate for malignant hyperthermia susceptibility. Genomics 1992;14:829-31.
33. Sudbrak R, Procaccio V, Klausnitzer M, et al. Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am J Hum Genet 1995;56:684-91.
34. Robinson RL, Monnier N, Wolz W, et al. A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees. Hum Mol Genet 1997;6:953-61.
35. Stewart SL, Hogan K, Rosenberg H, Fletcher JE. Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNAIS) in a North American family with malignant hyperthermia. Clin Genet 2001;59:178-84.
36. Iles DE, Lehmann-Horn F, Scherer SW, et al. Localization of the gene encoding the alpha-2/delta subunits of the L-type voltage dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hypothermia susceptible families. Hum Mol Genet 1994;3:969-75.
37. Ali SZ, Taguchi A, Rosenberg H. Malignant hyperthermia. Best Pract Res Clin Anaesthesiol 2003;17:519-33.
38. Moslehi R, Langlois S, Yam I, Friedman JM. Linkage of malignant hyperthermia and hyperkalemic periodic paralysis to the adult skeletal muscle sodium channel (SCN4A) gene in a large pedigree. Am J Med Genet 1998;76:21-7.
39. Robinson R, Hopkins P, Carsana A, et al. Several interacting genes influence the malignant hyperthermia phenotype. Hum Genet 2003;112:217-18.
40. Sei Y, Sambuughin NN, Davis EJ, et al. Malignant hyperthermia in North America: genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 2004;101:824-30.